Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Summary
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Official title: Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-03-17
Completion Date
2027-09
Last Updated
2026-04-01
Healthy Volunteers
No
Interventions
Epcoritamab
Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applications)
Gemcitabine (1000 mg/m2)
Subjects will receive gemcitabine 1000 mg/m2 on days 1 and 15 of the three 21-day cycles.
Oxaliplatin
Subjects will receive oxaliplatin 100 mg/m2 on day 1 of three 21-day cycles.
Locations (1)
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, Mexico